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a b s t r a c t
The dosage and frequency of a chemotherapy regimen are important determinants for its
success. Many research studies have attempted to identify optimal treatment strategies
for certain purposes such as minimizing the tumor burden, maximizing the normal cells as
well as the dose, andminimizing cytotoxicity to normal cells. In this paper, a combination of
mathematical and numerical analysis is applied to study the effect of initial tumor biomass
using a competition model describing tumor–normal cell interaction with periodically
pulsed chemotherapy. Someproperties of the set of initial tumor andnormal cell biomasses
for successful treatment are derived. On the basis of these properties, a numerical method
is constructed for locating the boundary of such a set. The boundary identifies the ability of
a chemotherapeutic treatment to eliminate a tumor. The optimal dosage and frequency for
a large tumor are discussed. The numerical results show that tumor–host interactions have
a great effect on the outcome of the treatment. The effect of resistant tumor subpopulations
is also discussed.
© 2011 Elsevier Ltd. All rights reserved.
1. Introduction
Surgery is often the primary procedure for removing a large tumor. It is followed by radiotherapy, chemotherapy, or
immunotherapy to provide a better chance of eliminating residual affected cells or metastatic cancer cells. But in several
cases, surgery is not feasible for undetectable cancer, or cancer that is not in a solid tumor, and chemotherapy becomes
the main treatment procedure in these situations [1]. Also as a systemic treatment, chemotherapy is employed against
metastatic cancers. When chemotherapy is administered, it destroys not only the tumor cells but also the surrounding
normal cells. Criteria for keeping normal cells above acceptable levels should be incorporated into the design of dosing
regimens for anticancer drugs. Also since chemotherapy often fails in the long term due to the development of resistant
subpopulations, we should examine how drug resistance affects the ability of the therapy to eliminate a large tumor.
Many research studies have attempted to identify optimal treatment strategies for certain purposes such as minimizing
the tumor burden, maximizing the normal cells as well as the dosage, and minimizing cytotoxicity to normal cells [2–7].
Panetta [8] andMatveev and Savkin [6] took the tumor–host interaction into account. They noted that there is evidence of the
existence of interactions between certain kinds of cancer and normal cells in some previous research studies. In this paper,
a mathematical model of periodically pulsed chemotherapy is considered. The rates of change of the normal and tumor cells
are formulated in terms of logistic growth. Competition between the normal and tumor cells, as well as a drug-induced
resistant subpopulation, is considered in the model. The dimensional form is as follows:
dX
dT
= r1X

1− X
K1
− λ1(Y1 + Y2)

, (1)
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dY1
dT
= r2Y1

1− Y1 + Y2
K2
− λ2(X + Y2)

, (2)
dY2
dT
= r3Y2

1− Y1 + Y2
K2
− λ3(X + Y1)

, (3)
X(nσ+) = F(D)X(nσ−), (4)
Y1(nσ+) = (F¯(D)− R(D))Y1(nσ−), (5)
Y2(nσ+) = F˜(D)Y2(nσ−)+ R(D)Y1(nσ−), (6)
where F(D) = e−α1D, F¯(D) = e−α2D, F˜(D) = e−α3D, and R(D) = e−rD. Variables X, Y1, and Y2 represent the normal, tumor,
and resistant cell biomasses, respectively. Parameters ri, i = 1, 2, 3, are the intrinsic growth rates; Ki, i = 1, 2, are the
carrying capacities; and λi > 0, i = 1, 2, 3, are the competitive parameters of the normal and tumor cells. Parameter σ is
the period of a given dose D and σ− and σ+ denote times just before and after a pulse, respectively. Functions F(D), F¯(D),
and F˜(D) are survival fractions of normal, tumor, and resistant cells for a dose D and R(D) is the fraction of tumor cells
mutating to resistant cells after a dose D. This model assumes that the chemotherapeutic drug destroys cells just after it is
administered. Eqs. (1)–(6) were first developed by Panetta [8]. In his study, conditions of acceptable dose and period were
obtained for preventing a tumor from recurring after attempts to surgically remove themajor tumormass. These conditions
depend on the competing effect in which normal and tumor cells exhibit negative and inhibiting effects on each other. Thus,
the growth of the normal cells is inhibited during the time period between two consecutive doses when the initial tumor
biomass is considered. Consequently, the normal cells may fall below acceptable levels in the treatment even if the criteria
in Panetta’s work are satisfied, since, in these criteria, the initial tumor biomass size was not considered.
Using the following nondimensional transformations together with parameters:
x = X
K1
, y1 = Y1K2 , y2 =
Y2
K2
, t = r1T , τ = r1σ α12 = λ1K2,
α21 = λ2K1, α31 = λ3K1, β = K2K1 , ρ1 =
r2
r1
, ρ2 = r3r1 ,
the nondimensional form of Eqs. (1)–(6) becomes
dx
dt
= x(1− x− α12(y1 + y2)), (7)
dy1
dt
= ρ1y1(1− (y1 + y2)− α21(x+ βy2)), (8)
dy2
dt
= ρ2y2(1− (y1 + y2)− α31(x+ βy1)). (9)
x(nτ+) = F(D)x(nτ−), (10)
y1(nτ+) = (F¯(D)− R(D))y1(nτ−), (11)
y2(nτ+) = F˜(D)y2(nτ−)+ R(D)y1(nτ−). (12)
Our goal in this paper is to determine the initial tumor andnormal biomasses for successful treatment and to study the factors
that affect the outcome of the therapy. Since many mathematical models, as well as Eqs. (1)–(3), assume logistic growth in
cell biomasses [9–12], mathematical analysis of the effect of initial tumor biomass size is difficult due to the nonlinearity of
the model. A combination of analytical and numerical techniques is developed to overcome this difficulty. Properties of the
set of initial cell populations for successful treatment are derived and a numerical method is then constructed to solve for
the set.
To provide details, some properties for the effect of initial tumor biomass size without a resistant subpopulation are
derived and the numerical methods are given in Section 2. The numerical method for obtaining the effect of the initial
tumor biomass size with resistant subpopulations is presented in Section 3. Some numerical examples and a discussion are
given in Section 4. Section 5 provides a brief conclusion.
2. The effect of initial tumor biomass size without a resistant subpopulation
2.1. Mathematical analysis
In this section, we consider the case without a resistant subpopulation, namely Y2 = 0. The nondimensional systemwith
y2 = 0 in Eqs. (7)–(12) becomes
dx
dt
= x(1− x− α12y1), (13)
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dy1
dt
= ρ1y1(1− y1 − α21x), (14)
x(nτ+) = F(D)x(nτ−), (15)
y1(nτ+) = F¯(D)y1(nτ−). (16)
It is important to analyze the local stability of the tumor-free equilibrium (1, 0) in the absence of chemotherapy. In this
case, only Eqs. (13) and (14) are considered. Whether a residual amount of tumor mass left after surgery will cause tumor
recurrence depends on the stability of this equilibrium. Examples from the in vitro experiments of interactions between
dermal fibroblasts and melanoma cells show that α21 < 1 and the tumor-free equilibrium is unstable [8]. The tumor will
recur unless it is completely removed. Now, we consider Eqs. (13)–(16). The tumor-free equilibrium in Eqs. (13) and (14)
becomes the tumor-free periodic solution in the absence of chemotherapy. Again, the stability of the tumor-free periodic
solution indicates whether a chemotherapy treatment is able to eliminate the residual amount of tumor mass or a tumor
with a restricted initial size. The tumor-free periodic solution was also studied by Panetta [8]. Following the notation and
tumor and normal conditions in Panetta’s work, let a be the survival fraction for normal tissues, so 1 − a represents the
percentage of allowable normal cell death. If τ and D are chosen to satisfy
ln
1− a
e−α1D − a < τ <
D(α2 − α1ρ1α21)
ρ1(1− α21) , (17)
then the normal tissue survives and the tumor does not recur. A stable limit cycle exists with y1 = 0. When α12 = 0, the
solution x(t) is independent of y1(0). Therefore, x(t) > a if x(0) > a/F(D) and if Eq. (17) is satisfied. On the other hand,when
α12 is large, the tumor cells possess a competitive advantage. The trajectories attracted to the limit cycle may fall below the
acceptable level during the treatment. Thus, successful chemotherapy depends on the initial tumor and normal cell biomass
sizes. Let Ω be the unit square and let E(τ ,D) ⊂ Ω be the set of initial tumor and normal cell biomasses attracted to the
stable limit cycle. The corresponding trajectories stay above the acceptable level during the treatment for dose D and period
τ .
Lemma 2.1. Let (u1(t), v1(t)) and (u2(t), v2(t)) be the solutions of Eqs. (13)–(14) with initial conditions (u1(0), v1(0)) ∈ Ω
and (u2(0), v2(0)) ∈ Ω , respectively. Assume that u1(0) = u2(0) and v2(0) < v1(0). Then,
u1(t) ≤ u2(t) and v2(t) ≤ v1(t) (18)
for t > 0.
Proof. Since u1(0) = u2(0) and v2(0) < v1(0), we have u˙1(0) < u˙2(0) from Eqs. (13)–(14). There exists a positive number
t0 such that Eq. (18) holds for t ≤ t0. Assume that t0 <∞ is the largest value for which Eq. (18) holds on [0, t0]. Then, either
u1(t0) = u2(t0) or v1(t0) = v2(t0) since (u1(t), v1(t)) and (u2(t), v2(t)) are continuous and are the unique solutions to the
corresponding initial value problems (IVP) onΩ . If u1(t0) = u2(t0) and v2(t0) < v1(t0), Eq. (18) is true for [0, t1]with some
number t1, t1 > t0. This contradicts the assumption that t0 is the largest such value. On the other hand, if v1(t0) = v2(t0)
and u1(t0) < u2(t0), then v˙2(t0) < v˙1(t0). There exists t1, t1 > t0, such that v2(t) ≤ v1(t) and u1(t) ≤ u2(t) for t ∈ [0, t1].
This also contradicts the assumption. Therefore, Eq. (18) holds for t > 0. 
From the proof in Lemma 2.1, we also have:
Lemma 2.2. Consider the same IVP in Lemma 2.1. Assume that u1(0) < u2(0) and v1(0) = v2(0). Then, u1(t) ≤ u2(t) and
v2(t) ≤ v1(t) for t > 0.
Let φt(x0, y0) = (φ(1)t (x0, y0), φ(2)t (x0, y0)) be the solution of Eqs. (13)–(16) with φ0+(x0, y0) = (F(D)x0, F¯(D)y0).
Lemma 2.3. Let x∗ = 1−F(D)eτF(D)(1−eτ ) . Then, limn→∞ φnτ−(x, 0) = (x∗, 0) for every x ∈ (0, 1).
Proof. Note that x∗ ∈ [a/F(D), 1] is the right endpoint of the stable limit cyclewhen (τ ,D) satisfies the tumor condition. Let
H(x) = φτ−(x, 0) = F(D)xeτ1−F(D)x+F(D)xeτ . Since H(0) = 0,H(1) < 1,H ′(x) > 0,H ′(0) = F(D)eτ = 1− F(D)x∗ + F(D)x∗eτ > 1
and H ′′(x) < 0, x∗ is the unique fixed point of H(x) for x ∈ (0, 1). Since H(x) is increasing on [0, 1] and H(x) > x on
(0, x∗),H(x) < x on (x∗, 1), the iteration x(n+1) = H(x(n)) converges to x∗ for x(0) ∈ (0, 1) by the Monotone Convergence
Theorem and continuity of H(x). 
Theorem 2.1. The set E(τ ,D) = {(u, v) ∈ Ω|u ≥ a/F(D), 0 ≤ v ≤ f (u)}, where f (u), u ∈ [a/F(D), 1], is nondecreasing.
Proof. Suppose that (u, v) ∈ E(τ ,D). Then, limn→∞ φnτ−(u, v) = (x∗, 0) and φ(1)t (u, v) ≥ a by the definition of E(τ ,D).
Consider (u1, v) with u1 > u. From Lemmas 2.1 and 2.2, φ
(1)
t (u1, v) ≥ φ(1)t (u, v) and φ(2)t (u1, v) ≤ φ(2)t (u, v). Thus,
φ
(1)
t (u1, v) ≥ a and limn→∞ φ(2)nτ−(u1, v) = 0. Since the tumor-free limit cycle is the only stable attractor for y1 = 0, we
have limn→∞ φnτ−(u1, v) = (x∗, 0). Consequently, (u1, v) ∈ E(τ ,D). Similarly, (u, v1) ∈ E(τ ,D) if v1 < v. Suppose that
f (u) = max0≤v≤1{(u, v)|(u, v) ∈ E(τ ,D)} for u ≥ a/F(D). Then, (u1, f (u)) ∈ E(τ ,D) for u1 > u and (u, v1) ∈ E(τ ,D) for
v1 < f (u). Therefore, f (u1) ≥ f (u)when u1 > u. This proves the argument in this theorem. 
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Corollary 2.1. Let f be defined as in the proof of Theorem 2.1 and suppose that v0 = f (u0) with u0 ∈ [a/F(D), 1]. Then
φτ−(u0, v0) falls either on the curve v = f (u), u ∈ [a/F(D), 1] or on the line segment joining (a/F(D), 0) and (a/F(D),
f (a/F(D))).
Proof. If φτ−(u0, v0) lies in the interior of E(τ ,D), then there exists v, v > f (u0), such that (u0, v) ∈ E(τ ,D) by Lemmas 2.1
and 2.2. This contradicts the definition of f . Therefore, φτ−(u0, v0) falls either on the line segment joining (a/F(D), 0) and
(a/F(D), f (a/F(D))) or on the curve v = f (u) for u ∈ [a/F(D), 1]. 
2.2. The numerical method
In order to determine E(τ ,D), it is sufficient to find the curve v = f (u). In the first case, we assume that
φ
(2)
τ− (a/F(D), f (a/F(D))) < f (a/F(D)). (19)
Then, φτ−(a/F(D), f (a/F(D))) lies on the line segment u = a/F(D), v < f (a/F(D)). From Theorem 2.1 and Corollary 2.1,
there exists a number u∗, u∗ ∈ (a/F(D), 1), such that φτ−(u, f (u)) satisfies
φ
(1)
τ− (u, v)− a/F(D) = 0 if u ∈ [a/F(D), u∗), (20)
φ
(2)
τ− (u, v) = f (φ(1)τ− (u, v)) if u ∈ [u∗, 1]. (21)
A numerical method will be developed for solving vi = f (ui) for a grid a/F(D) = u0 < u1 < · · · < uN = 1. Starting with
i = 0, Eq. (20) is solved for vi, i = 0, 1, 2, . . . . When the solution vi to Eq. (20) satisfies
φ
(2)
τ− (ui, vi) > v0 (22)
for some i > 1, Eq. (21) is solved instead of Eq. (20) for the remaining vi. Note that if Eq. (22) is satisfied when i = 1, u1
needs to be chosen closer to u0 for interpolation, which will be explained later in this subsection. Now, Eq. (20) is solved by
Newton’s method:
v(n+1) = v(n) − φ
(1)
τ− (u, v
(n))− a/F(D)
∂φ
(1)
τ−
∂v
(u, v(n))
(23)
with an initial value v(0). Eq. (21) is also solved by Newton’s method:
v(n+1) = v(n) − g(u, v
(n))
∂g
∂v
(u, v(n))
, (24)
where g(u, v) = φ(2)
τ− (u, v) − f (φ(1)τ− (u, v)). Let G(x, y1) be the vector field of Eqs. (13)–(14) and DG(x, y1) be the Jacobian
matrix of G. Consider the following ordinary differential equations (ODE):
(x˙, y˙1)T = G(x, y1), (25)
(P˙, Q˙ )T = DG(x, y1)(P,Q )T . (26)
Then,
∂φ
(1)
τ−
∂v
(u, v) = P(τ ) and φ
(2)
τ−
∂v
(u, v) = Q (τ ) are obtained by integrating Eqs. (25)–(26) over [0, τ ]with initial conditions
x(0) = F(D)u, y1(0) = F¯(D)v, P(0) = 0, and Q (0) = F¯(D).
Remark 2.1. The computation of f (u) and f ′(u) in Eq. (24) can be carried out by any suitable interpolation using data points
(ui, vi) with solved vi. For example, the numerical experiments in this paper employ linear interpolation using two solved
data points nearest to u.
The other case considered here is
φ
(2)
τ− (a/F(D), f (a/F(D))) ≥ f (a/F(D)). (27)
In this case, we also have
φ
(2)
τ− (1, f (1)) < f (1) (28)
by the properties of the set E(τ ,D) and the function f . Then, Eq. (21) is satisfied for u ∈ [a/F(D), 1]. In this case, there exists
a fixed point (u¯, v¯) of saddle type. From the numerical method for solving Eq. (21) in the first case, interpolations of data
points on v = f (u) have to be applied. Therefore, the fixed point and one additional point on each side of this fixed point
need to be solved first. To find the fixed point, a secant method is suggested for solving the nonlinear equation
h(u) = φ(2)
τ− (u, v)− v = 0, u ∈ [a/f (D), 1] (29)
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with φ(1)
τ− (u, v) = u. Note that for a fixed u value, φ(1)τ− (u, v) = u is solved for v by Newton’s method, similarly to Eq. (20).
The initial guesses for the secant method are u(0) = a/F(D) and u(1) = a/F(D)+ δ, where δ is a small and positive number.
Once the fixed point (u¯, v¯) is solved, the additional point on the curve v = f (u) to each side of (u¯, v¯) can be found by the
following procedure. Let stepu be the prescribed step size in u and suppose that u1 = u¯+ stepu. Since v = f (u) is invariant
under the map φτ− , (u1, v1) is solved via the minimization problem:
min
v∈[0,1] ‖φ
K
τ−(u1, v)− (u¯, v¯)‖, (30)
where ‖ · ‖ denotes the Euclidean norm and K > 0 is the number of maps. For example, K = 5 is used in our numerical
experiments. The minimizer employed in this paper is the Nelder–Mead simplex algorithm [13]. After (u¯, v¯) and (u1, v1)
are found, v2 = f (u2), . . . , vN = f (uN) with u2 < · · · < uN = 1 are computed by solving Eq. (21). The solutions
v−1 = f (u−1), . . . , v−M = f (u−M)with u¯− stepu = u−1 > · · · > u−M = a/F(D) are computed by the same procedure.
Here, the algorithm is given, to summarize the procedure for solving v = f (u) described in this subsection.
Algorithm 2.1. Step 1. Suppose that u0 = a/F(D). Solve Eq. (20) for v0. If φ(2)τ− (u0, v0) < v0, do Steps 2–3. Otherwise, do
Steps 4–6.
Step 2. Suppose that a/F(D) = u0 < u1 < · · · < uN = 1. Solve Eq. (20) for vi while φ(2)τ (ui, vi) ≤ v0 for i = 1, . . . , i∗.
Step 3. When φ(2)τ (ui, vi) > v0 for some i, i = i∗ + 1, solve Eq. (21) for i = i∗ + 1, . . . ,N .
Step 4. Suppose that u(0) = a/F(D) and u(1) = a/F(D) + δ. Compute h(u(0)) and h(u(1)). Then, solve Eq. (29) by the secant
method and let the solution (fixed point) be (u¯, v¯).
Step 5. Suppose that u¯ < u1 < · · · < uN = 1. Solve Eq. (30) for v1 and then solve Eq. (21) for vi with ui, i = 2, . . . ,N .
Step 6. Suppose that u¯ > u−1 > · · · > u−M = a/F(D). Solve Eq. (30) for v−1 with u1 = u−1 and then solve Eq. (21) for v−i
with u−i, i = −2, . . . ,−M .
3. The effect of initial tumor biomass size with a resistant subpopulation
In this section, the three-dimensional model, Eqs. (7)–(12), is considered. In a special case, suppose that ρ1 = ρ2
and α21 = α31, and assume that there is no competition between y1 and y2 such that βy2 and βy1 are removed from
Eqs. (8) and (9), respectively. The normal biomass x and total tumor biomass y1 + y2 satisfy the properties in Lemmas 2.1
and 2.2. As pointed out by Panetta [8], the assumptions ρ1 = ρ2 and α21 = α31 are biologically reasonable. Now, suppose
that Ω˜ = [0, 1] × [0, 1] × [0, 1] and let E˜(τ ,D) ⊂ Ω˜ be the set of the initial normal, tumor and resistant biomasses
(u, v, w) ∈ Ω˜ attracted to the tumor-free limit cycle. The corresponding trajectories remain above the acceptable level
during the treatment for dose D and period τ . Since the resistant subpopulation considered in this paper is mutated from
the administration of drugs, it is assumed that Y2(0) = 0. Therefore, we are interested in the set E(τ ,D) = E˜(τ ,D) ∩ Ω
defined in the same way as in Section 2.
Proposition 3.1. Suppose that ρ1 = ρ2, α21 = α31, and βy2 and βy1 are removed from Eqs. (8) and (9), respectively. If
(u, v, w) ∈ E˜(τ ,D), then (u, v, w1) ∈ E˜(τ ,D) when w1 < w; (u, v1, w) ∈ E˜(τ ,D) when v1 < v; and (u1, v, w) ∈ E˜(τ ,D)
when u1 > u.
The proof of this proposition is similar to the proof in Theorem 2.1. Suppose a chemotherapy treatment eliminates a tumor
with initial biomasses (u, v, w). From Proposition 3.1,
E˜(τ ,D) = {(u, v, w) ∈ Ω˜|u ≥ a/F(D), v ≤ v˜(u), 0 ≤ w ≤ f˜ (u, v)}, (31)
where 0 ≤ v˜(u) ≤ 1 is nondecreasing and f˜ (u, v) is nondecreasing in u and nonincreasing in v. Note that f˜ (u, v˜(u)) = 0 if
v˜(u) < 1 and E(τ ,D) = {(u, v) ∈ Ω|u ≥ a/F(D), 0 ≤ v ≤ v˜(u)}.
In the general case, we cannot prove results similar to Lemmas 2.1 and 2.2 for Eqs. (7)–(12). However, it is reasonable
to assume that an effective chemotherapy treatment satisfies Proposition 3.1 and Eq. (31). Then, the method developed
for the first case in Section 2.2 can be easily extended to find v˜(u) and f˜ (u, v). For simplicity, we will work on only the
case with the assumption that the chemotherapy is able to reduce the tumor size at τ− after the first dose. Again, let
φ˜t(u0, v0, w0) = (φ˜(1)t (u0, v0, w0), φ˜(2)t (u0, v0, w0), φ˜(3)t (u0, v0, w0))be the solution of Eqs. (7)–(12)with φ˜0+(u0, v0, w0) =
(F(D)u0, (F¯(D)− R(D))v0, F˜(D)w0 + R(D)v0) and let u ∈ [a/F(D), 1] be fixed. The function v = v˜(u) satisfies
φ˜
(1)
τ− (u, v, 0)− a/F(D) = 0 if u ∈ [a/F(D), u∗), (32)
φ˜
(3)
τ− (u, v, 0) = f˜ (φ˜(1)τ− (u, v, 0), φ˜(2)τ− (u, v, 0)), if u ∈ [u∗, 1], (33)
where u∗ ∈ (a/F(D), 1). When u > u∗, the solution v to Eq. (32) satisfies φ˜(3)
τ− (u, v, 0) > f˜ (a/F(D), φ˜
(2)
τ− (u, v, 0)). This
implies that (u, v, 0) ∉ E˜(τ ,D). Then, Eq. (33) has to be solved instead of Eq. (32). To solve Eqs. (32)–(33), Newton’smethods
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in Eqs. (23) and (24) are modified as
v(n+1) = v(n) − φ˜
(1)
τ− (u, v
(n), 0)− a/F(D)
∂φ˜
(1)
τ
∂v
(u, v(n), 0)
, (34)
and
v(n+1) = v(n) − g˜(u, v
(n), 0)
∂ g˜
∂v
(u, v(n), 0)
, (35)
respectively,with an initial valuev(0). The function g˜ is definedby g˜(u, v, w) = φ˜(3)
τ− (u, v, w)−f (φ˜(1)τ− (u, v, w), φ˜(2)τ− (u, v, w)).
Let G˜(x, y1, y2) be the vector field of Eqs. (7)–(9) and DG˜(x, y1, y2) be the Jacobian matrix of G˜. Consider the following ODE:
(x˙, y˙1, y˙2)T = G˜(x, y1, y2), (36)
(P˙, Q˙ , S˙)T = DG˜(x, y1, y2)(P,Q , S)T . (37)
Then,
∂φ
(1)
τ−
∂v
(u, v, 0) = P(τ ), φ
(2)
τ−
∂v
(u, v, 0) = Q (τ ), and φ
(3)
τ−
∂v
(u, v, 0) = S(τ ) are obtained by integrating Eqs. (36)–(37) over
[0, τ ] with initial conditions x(0) = F(D)y, y1(0) = (F¯(D) − R(D))v, y2(0) = R(D)v, P(0) = 0,Q (0) = F¯(D) − R(D), and
S(0) = R(D).
Next, let (u, v) ∈ Ω be fixed with u ∈ [a/F(D), 1] and 0 ≤ v ≤ v˜(u). Thenw = f˜ (u, v) satisfies either
φ˜
(1)
τ− (u, v, w) = a/F(D) (38)
or
φ˜
(3)
τ− (u, v, w) = f˜ (φ˜(1)τ− (u, v, w), φ˜(2)τ− (u, v, w)). (39)
Again, when a solution w to Eq. (38) satisfies φ˜(3)
τ− (u, v, w) > f˜ (a/F(D), φ˜
(2)
τ− (u, v, w)), we can conclude that (u, v, w) ∉
E˜(τ ,D). Then, Eq. (39) should be solved. Newton’s method for solving Eqs. (38) and (39) is given by
w(n+1) = w(n) − φ˜
(1)
τ− (u, v, w
(n))− a/F(D)
∂φ˜
(1)
τ−
∂w
(u, v, w(n))
, (40)
and
w(n+1) = w(n) − g˜(u, v, w
(n))
∂ g˜
∂w
(u, v, w(n))
, (41)
respectively, with an initial value w(0). The derivatives
∂φ
(1)
τ−
∂w
(u, v, w) = P(τ ), φ
(2)
τ−
∂w
(u, v, w) = Q (τ ), and φ
(3)
τ−
∂w
(u, v, w) =
S(τ ) are obtained by integrating Eqs. (36)–(37) over [0, τ ] with initial conditions x(0) = F(D)u, y1(0) = (F¯(D) −
R(D))v, y2(0) = R(D)v + F˜(D)w, P(0) = 0,Q (0) = 0, and S(0) = F˜(D). Again, the computation of f˜ (u, v) and its first
partial derivatives in Eqs. (35) and (41) can be carried out by interpolation using data points (ui, vj, wij)with solvedwij.
The procedure for solving f˜ is summarized in the following algorithm.
Algorithm 3.1. Step 1. Suppose that u0 = a/F(D). Solve Eq. (32) for v0 with u = u0. Suppose that 0 = v00 < v01 < · · · <
v0N0 = v0. For j = 0, 1, . . . ,N0 − 1, solve Eq. (38) forw0j with u = u0 and v = v0j.
Step 2. Suppose that a/F(D) = u0 < u1 < · · · < uN = 1. For i = 1, . . . ,N , do Steps 3–4.
Step 3. Solve Eq. (32) for vi with u = ui. If φ˜(3)τ (ui, vi, 0) > f˜ (u0, φ˜(2)τ− (ui, vi, 0)), solve Eq. (33) for vi again with u = ui.
Step 4. Suppose that 0 = vi0 < vi1 < · · · < viNi = vi. For j = 0, 1, . . . ,Ni− 1, solve Eq. (38) forwij with u = ui and v = vij.
If φ˜(3)
τ− (ui, vij, wij) > f˜ (u0, φ˜
(2)
τ− (uij, vij, wij)), solve Eq. (39) forwij again with u = ui and v = vij.
4. Numerical simulations and discussion
In this paper, we are most interested in the size of a tumor that successive treatments with a fixed dose D and period τ
can eliminate, i.e. the set E(τ ,D) defined in Section 2. Throughout this paper, the numerical ODE integrator is a fourth-order
Runge–Kutta scheme with adaptive step size control [14].
In this study, the parameter values are fixed at
α21 = 0.7, ρ = 2.0, α1 = 1.0 α2 = 4.0, a = 0.5. (42)
The negative effect on the growth of cancer cells due to tumor–normal cell interaction is α21 = 0.7. We assume also that
α21 = α31. Cancer cells are assumed to grow twice as fast as normal cells, that is, ρ = 2.0. The percentage of allowable
normal tissue death is 1− a = 50%.
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Fig. 1. The effect of initial tumor and normal biomass sizes without a resistant subpopulation at various D, τ , and α12 values.
4.1. The effect of tumor–host interactions
The examples in this subsection focus on the effect of tumor–host interactions using Eqs. (13)–(16) when there is no
resistant subpopulation. The dosage values are selected at D = 0.3, 0.4, and 0.5, so the ratios of survival fractions of normal
cells to tumor cells are 2.46, 3.32, and 4.48, respectively. Eq. (17) defines acceptable τ values assuming that y1(0) ≈ 0.
Suppose that D = 0.5. Eq. (17) gives 1.54 < τ < 2.16. Note that the nondimensional variable τ denotes τ/r1 days. For
example, τ = 2.16 is 10.2 days if the intrinsic growth rate of normal cells is r1 = 0.212 as in [8]. When α12 = 0.0, the
growth of normal cells is independent of the size of the tumor. Directly integrating Eqs. (13)–(16) with any initial condition
in [a/F(D), 1]× [0, 1] and any τ value satisfying Eq. (17) shows that the solution is attracted to the tumor-free steady state.
From Theorem 2.1, f (u) = 1 for u ∈ [a/F(D), 1] and thus E(τ ,D) = [a/F(D), 1] × [0, 1]. An acceptable (τ ,D) is able to
eliminate a tumor of any size as long as x(0) ≥ a/F(D). However, we believe that the case with tumor–host interaction
α12 > 0 is more realistic since there is competition for nutrients even if there is no direct interaction.
Now, consider α12 = 0.5. Tumor cells exhibit a negative effect on normal cells but the effect is not strong. Fig. 1(a)–(c)
show E(τ ,D) for D = 0.3, 0.4, and 0.5 with various τ values. Each curve represents the boundary of E(τ ,D) for specified
α12,D, and τ values. For example, select α12 = 0.5,D = 0.4, and τ = 1.4. Adopting the definition of E(τ ,D) from
Theorem 2.1, the boundary of E(1.4, 0.4) is computed using Algorithm 2.1. The set E(1.4, 0.4) is the shaded region in
Fig. 2, i.e., with the initial conditions in this set, the tumor vanishes after a large number of cycles. Fig. 1(a)–(c) indicate
that successive treatments with a longer period between them are able to kill a larger tumor than ones with a shorter period
between them if the dose D is fixed. Thus, the largest period in Eq. (17) is considered the best period in this situation. A
longer recess allows more normal cells to regrow, preventing excessive destruction of them in the next treatment. Among
the different dosage values in our study, E(2.16, 0.5) ⊂ E(1.73, 0.4) ⊂ E(1.29, 0.3). This agrees with the general belief that
long-time exposure to the drug at modest concentrations would have a much better effect than successive pulsed supplies
of the drug at high concentration [1]. Fig. 1(a)–(c) also show that a longer time period is needed for recovery when a high
concentration of the drug is administrated.
Since tumor cells grow faster than normal cells, tumor cells have a larger inhibiting effect on the growth of normal cells.
This corresponds to a larger α12 value and may cause there to be insufficient normal cell biomass for the host to survive.
Fig. 1(d)–(f) show E(τ ,D) forα12 = 1.2. ForD = 0.3 and 0.4, the largest τ value satisfying Eq. (17)may not be the best choice
for any initial tumor size. Suppose that we have treatment A = (τ ,D) = (1.0, 0.3) and treatment B = (1.29, 0.3). Note that
(0.98, 0.47) ∈ E(1.0, 0.3) but (0.98, 0.47) ∉ E(1.29, 0.3). That is, treatment A is acceptable for the initial cell population
(0.98, 0.47)while treatment B is not. Starting with (0.98, 0.47), the orbits (dots) under the map φτ− for treatments A and B
are plotted in Fig. 3. When the cell biomasses (x, y1) lie above the nullcline of x (dotted line), the normal cells decrease with
time. The longer period τ results in smaller normal cell biomass and hence gives a higher risk of excessive damage to the
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E(1.4,0.4)
Fig. 2. The set E(1.4, 0.4), the shaded region, with its boundary plotted along the curve where α12 = 0.5.
Fig. 3. When the cell biomass lies above the nullcline of x (dotted curve) during the recess between two doses, treatment Awith a smaller τ value is better
than treatment Bwith a larger τ value.
normal cells. Fig. 3 shows that the cell biomasses at the end of the first dose, φτ−(0.98, 0.47), are above the nullcline of x for
both treatments A and B. Treatment B gives smaller normal tissue biomass and larger tumor biomass than treatment A at the
end of the first dose since treatment A has a shorter period. For treatment B, the normal cells fall below a/F(D) at the end of
the third cycle and they fall below the acceptance level right after the fourth dose; the dashed curve presents x = a/F(D). On
the other hand, treatment A is successful since the normal tissue biomass is maintained above the acceptable level a/F(D).
Therefore, a larger τ value becomes a drawback if the cell populations grow above the nullcline of x.
For an even larger α12 value, e.g. α12 = 1.6, the tumor has a competitive advantage. The limit cycle with x = 0 becomes
stable under some conditions. The location and stability conditions of the limit cycle with x = 0 are found using a similar
analysis of the tumor-free limit cycle. For example, the limit cycle with x = 0 is stable at D = 0.5 if τ > 1.83. This, along
with Eq. (17), shows that both limit cycles are locally stable at D = 0.5 if 1.83 < τ < 2.16. For the map φτ− , there exist
(i) two stable fixed points, one with x = 0 and the other with y1 = 0, (ii) one fixed point of saddle type, and (iii) a separatrix
through the fixed point. The separatrices (lines) and the unstable fixed points (dots) at selected τ values shown in Fig. 4(a) are
computed by Steps 4–6 in Algorithm 2.1. Here, u¯ > u−1 > · · · > u−M = a/F(D) is changed to u¯ > u−1 > · · · > u−M = 0 in
Step 6 for computing separatrices. The basin of attraction of the tumor-free limit cycle shrinks as τ increases. Now, suppose
that τ = 2.0. Two initial conditions chosen above and below the separatrix (line) are attracted to different attractors as
shown in Fig. 4(b) with corresponding orbits (circles) under the map φτ− . Fig. 4(a) shows that a treatment with a smaller
τ value is able to eliminate a larger tumor. On the other hand, as previously mentioned, a smaller τ value gives a higher
risk of overdose to the host. Thus, short and long periods are not effective for a fixed dosage when α12 is large, as shown in
Fig. 1(g)–(i). The period should be long enough to allow normal cells to recover yet not too long to prevent the tumor from
growing too large and exhibiting a strong negative effect on the normal cells. In all cases shown in Fig. 1, smaller dosages
with corresponding optimal periods are able to kill larger tumors. Although larger dosages give a higher ratio of survival
H.-C. Wei et al. / Computers and Mathematics with Applications 61 (2011) 3117–3127 3125
a b
Fig. 4. (a) The separatrices of the basins of attraction when Eqs. (13)–(16) possess two stable limit cycles at some selected τ values. (b) Two points, one
on each side of the separatrix, are attracted to different attractors under the map φτ− .
fractions of normal cells to tumor cells, they also produce a higher risk of overdosing the host. It is worth noting that all
curves in Fig. 1, except for the largest τ value in each of Fig. 1(g)–(i), satisfy Eq. (19) and are computed with Steps 2–3 of
Algorithm 2.1. The exceptions satisfy Eq. (27) and are computed with Steps 4–6.
4.2. Resistant subpopulations
For preventing tumor recurrence, the conditions for the acceptable D and τ values with the presence of a resistant
subpopulation are given by
τ > ln
1− a
F(D)− a , (43)
τ <
1
ρ1(1− α21) ln
F(D)α21ρ1
F¯(D)− R(D) , (44)
τ <
1
ρ2(1− α31) ln
F(D)α31ρ2
F˜(D)
, (45)
in [8].
Recall that the largest period for a fixed dosage can yield elimination of the largest tumor within the acceptable D and τ
values if α12 is not large and if there is no resistant subpopulation. We consider α12 = 0.5 in this subsection. The parameter
values are fixed at
α12 = 0.5, α21 = α31 = 0.7, ρ1 = ρ2 = 2.0,
α1 = 1.0, α2 = 4.0, β = 0.5, a = 0.5. (46)
Other parameters α3,D, τ , and r will be selected to satisfy Eqs. (43)–(45) with the largest acceptable τ value for the efficacy
and safety of the treatment. Eqs. (43)–(46) imply that the tumor-free periodic solution is unstable when α3 < 2.6 for any
dose and period. That is, the tumor is untreatable if α3 < 2.6. As previously mentioned, this paper focuses on initial tumor
sizes that a successful treatment is able to eliminate. We will not consider the untreatable case here. Thus, 2.6 < α3 < α2
is assumed. Suppose that α3 = 3.0. Then, D = 0.3 is an acceptable dose while D = 0.5 and D = 0.4 are not. Suppose that
D = 0.3 and r = 5.0. The corresponding largest τ value is 0.79. The fraction of the tumor cells mutating to the resistant
subpopulation due to a dose of drug is R(0.3) = 22%. Fig. 5 shows E˜(0.79, 0.3), which is the region under the surface. Every
initial point (x, y1, y2) ∈ E˜(0.79, 0.3) is attracted to the tumor-free limit cycle with τ = 0.79 and D = 0.3. Since tumor
cells are assumed to be mutated to resistant subpopulations as a result of exposure to chemotherapeutic drugs, y2(0) = 0
is assumed. Therefore, we are interested only in E(0.79, 0.3), which is the region on the xy1-plane bounded by the curve
shown in Fig. 5. However, E˜ still needs to be computed since v˜ in Eq. (31) is dependent on E˜.
We now investigate the difference between the cases with and without a resistant population. Again, suppose that
D = 3.0, r = 5.0, and τ = 0.79 for α2 = 4.0 and α3 = 3.0 where 30% of the sensitive cells can survive a dose of the
drug and 41% of the resistant cells can survive, respectively. Fig. 6(a) shows that chemotherapy is able to eliminate a large
tumor without a resistant population. The set E(1.29, 0.3) without a resistant population for α2 = 4.0 is the region that
lies to the right of the solid curve. The set E(0.79, 0.3) with a resistant subpopulation for α2 = 4.0 and α3 = 3.0 is the
region below the dotted curve. E(0.79, 0.3) for α2 = 4.0 and α3 = 3.0 is much smaller than E(1.29, 0.3) for α2 = 4.0.
With a resistant subpopulation, the therapy is able to eliminate a tumor only 1/4 to 1/2 of the size of a tumor that could
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Fig. 5. The set E˜(0.79, 0.3), which lies under the surface, and the set E(0.79, 0.3) bounded by the curve on the xy1-plane.
a b
Fig. 6. The effect of (a) dosages and strength of resistance on the initial tumor size, (b) fractions of the tumor cells mutating to resistant cells due to a dose
of drug.
be eliminated without a resistant subpopulation. Suppose that α2 = 4.0 and α3 = 2.9 where 42% of the resistant cells can
survive a dose. The region E(0.74, 0.3) below the dashed curve for α2 = 4.0 and α3 = 2.9 becomes very small. It is very
easy for tumor recurrence to occur even with a small residual amount of tumor mass left after surgery. Thus, the strength of
resistance also has a large effect on the ability to eliminate a large tumor. Finally, suppose that D = 0.3 and r = 5.0, 6.0, 7.0,
and 8.0. Then, the fractions R(D) of tumor cells mutating to a resistant subpopulation are 22%, 17%, 12%, and 9%, respectively.
Fig. 6(b) shows that a given dose can eliminate a larger tumor with a smaller fraction of cells mutating.
5. Conclusion
The dosage of a chemotherapeutic agent is an important factor for its success. Some studies have suggested that the
optimal drug administration for minimizing the tumor burden is an initial maximum dose associated with an acceptable
level of normal cell biomass followed by continuous infusion at a modest rate such that the normal cell biomass is kept at
that level [3,5,6]. However, it has been reported that a larger dosage than needed is often used in medical practice [7,15].
In this paper, analytical and numerical techniques are applied to a mathematical model of periodically pulsed
chemotherapy. The tumor-free case is the basic configuration of the mathematical model since it gives the necessary
conditions for preventing a tumor from recurring. The stability conditions of the tumor-free periodic solution were derived
by Panetta [8]. However, these conditions are not sufficient for predictingwhether the tumorwill recur, because this depends
not only on the stability properties of the tumor-free periodic solution but also the residual amount of tumor mass left after
surgery. Taking one step further than Panetta’s work, the effect of the initial tumor size is studied by finding the basin of
attraction of the tumor-free periodic solution. The maximum residual amount of tumor mass or the maximum initial size of
a tumor which a given dose and period is able to eliminate is then determined. This gives better predictions of whether the
tumor will recur and whether surgery is necessary.
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Critical parameters, such as the tumor–host interaction, survival fraction of resistant cells, and percentage of tumor
cells induced to have resistance, are studied. The size of the basin of attraction is highly sensitive to these parameters.
The negative and inhibiting effect of the tumor cells on the normal cells α12 may depend on the interindividual variability.
This is an important factor that causes the normal cells to fall below the acceptable level when the initial tumor size is
considered. Knowing the effect of α12 is able to help one determine safer methods of delivering chemotherapy andmay also
help individualize therapy. The numerical results show that formoderateα12 values, a longer time period between twodoses
is better to protect the host from overdosing. Smaller dosages with corresponding optimal time intervals are better than
larger dosages regardless of the appearance of the resistant subpopulation. When a tumor develops resistance, it becomes
untreatable if we have for the survival fractions F˜(D) ≪ F¯(D). We do not consider this situation here since it needs more
sophisticated resistance models. Panetta [16] considered a heterogeneous tumor model with chemotherapy and induced
drug resistance. The administration of non-cross-resistant drugs, which was applicable for the case of F˜(D) ≪ F¯(D), was
studied as regards preventing tumor recurrence in Panetta’s work. It helped determinemore effectivemethods of delivering
combination chemotherapy. Even if the survival fraction F˜(D) is chosen not much smaller than F¯(D), such that successful
treatment is possible, in this paper, the range of acceptable dose and period becomesmuch smaller than for the casewithout
a resistant subpopulation. Furthermore, a small change in the survival fraction F˜(D) will significantly shrink the basin of
attraction E(τ ,D). Thus, it is important to account for the resistant subpopulation. It is expected that these results could be
applied in clinical practice. Further studies including clinical tests are needed to verify these results.
Acknowledgements
The authors would like to thank Ms. Emi Higashiyama for her help with editing this manuscript. This research work was
supported by Feng Chia University under the grant FCU10G27221.
References
[1] S.S. Feng, S. Chien, Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of
cancer and other diseases, Chem. Eng. Sci. 58 (2003) 4087–4114.
[2] Z. Agur, R. Arnon, B. Schechter, Reduction of cytotoxicity to normal tissues by new regimens of cell-cycle phase-specific drugs, Math. Biosci. 92 (1988)
1–15.
[3] D. Barbolosi, A. Iliadis, Optimizing drug regimens in cancer chemotherapy: a simulation study using a PK–PD model, Comput. Biol. Med. 31 (2001)
157–172.
[4] K.R. Fister, J.C. Panetta, Optimal control applied to cell-cycle-specific cancer chemotherapy, SIAM J. Appl. Math. 60 (3) (2000) 1059–1072.
[5] A. Iliadis, D. Barbolosi, Optimizing drug regimens in cancer chemotherapy by an efficacy–toxicity mathematical model, Comput. Biomed. Res. 33
(2000) 211–226.
[6] A.S.Matveev, A.V. Savkin, Application of optimal control theory to analysis of cancer chemotherapy regimens, SystemsControl Lett. 44 (2002) 311–321.
[7] J.C. Panetta, J. Adam, A mathematical model of cycle-specific chemotherapy, Math. Comput. Modelling 22 (2) (1995) 67–82.
[8] J.C. Panetta, A mathematical model of periodically pulsed chemotherapy: tumor recurrence and metastasis in a competitive environment, Bull. Math.
Biol. 58 (3) (1996) 425–447.
[9] S. Michelson, J.T. Leith, Unexpected equilibria resulting from differing growth rates of subpopulations within heterogeneous tumors, Math. Biosci. 91
(1988) 119–129.
[10] S. Michelson, J.T. Leith, Growth factors and growth control of heterogeneous cell populations, Bull. Math. Biol. 55 (5) (1993) 993–1011.
[11] S. Michelson, J.T. Leith, Interlocking triads of growth control in tumors, Bull. Math. Biol. 57 (2) (1995) 345–366.
[12] J.C. Panetta, A logistic model of periodic chemotherapy with drug resistance, Appl. Math. Lett. 10 (1) (1997) 123–127.
[13] J.A. Nelder, R. Mead, A simplex method for function minimization, Comput. J. 7 (1965) 308–313.
[14] W.H. Press, S.A. Teukolsky, W.T. Vetterling, B.P. Flannery, Numerical Recipes in C++, Cambridge University Press, 2002.
[15] S. Bunimovich-Mendrazitsky, H. Byrne, L. Stone, Mathematical model of pulsed immunotherapy for superficial bladder cancer, Bull. Math. Biol. 70 (3)
(2008) 2055–2076.
[16] J.C. Panetta, A mathematical model of drug resistance: heterogeneous tumors, Math. Biosci. 147 (1998) 41–61.
